Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia

References

• BrownJRHallekMJPagelJMChemoimmunotherapy versus targeted treatment in chronic lymphocytic leukemia: when, how long, how much, and in which combination?Am Soc Clin Oncol Educ Book201635e387e39827249745
   PubMedGoogle Scholar
• FischerKCramerPBuschRBendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupJ Clin Oncol2011293559356621844497
   PubMed Web of Science ®Google Scholar
• HallekMFischerKFingerle-RowsonGAddition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialLancet20103761164117420888994
   PubMed Web of Science ®Google Scholar
• ExtermannMOvercashJLymanGHParrJBalducciLComorbidity and functional status are independent in older cancer patientsJ Clin Oncol199816158215879552069
   PubMed Web of Science ®Google Scholar
• DöhnerHStilgenbauerSBennerAGenomic aberrations and survival in chronic lymphocytic leukemiaN Engl J Med20003431910191611136261
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSPlunkettWLong-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Blood20141243059306425281606
   PubMed Web of Science ®Google Scholar
• ThomsonPATamCSO’BrienSMFludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemiaBlood201612730330926492934
   PubMedGoogle Scholar
• FischerKBahloJFinkAMLong-term remission after FCR chemotherapy in previously untreated patients with CLL: updated results of the CLL8 trialBlood201612720821526486789
   PubMed Web of Science ®Google Scholar
• HallekMSignaling the end of chronic lymphocytic leukemia: new frontline treatment strategiesBlood20131223723373424065239
   PubMed Web of Science ®Google Scholar
• CramerPHallekMEichhorstBState-of-the-art treatment and novel agents in chronic lymphocytic leukemiaOncol Res Treat201639253226890007
   PubMed Web of Science ®Google Scholar
• BenjaminiOJainPTrinhLSecond cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomesLeuk Lymphoma2015561643165025308294
   PubMed Web of Science ®Google Scholar
• HillmenPRobakTJanssensAChlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialLancet20153851873188325882396
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRObinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsN Engl J Med20143701101111024401022
   PubMed Web of Science ®Google Scholar
• BurgerJATedeschiABarrPMIbrutinib as initial therapy for patients with chronic lymphocytic leukemiaN Engl J Med20153732425243726639149
   PubMed Web of Science ®Google Scholar
• AdvaniRHBuggyJJSharmanJPBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesJ Clin Oncol201331889423045577
   PubMed Web of Science ®Google Scholar
• HonigbergLASmithAMSirisawadMThe Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProc Natl Acad Sci U S A2010107130751308020615965
   PubMed Web of Science ®Google Scholar
• DubovskyJABeckwithKANatarajanGIbrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesBlood20131222539254923886836
   PubMed Web of Science ®Google Scholar
• ByrdJCFurmanRRCoutreSEThree-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibBlood20151252497250625700432
   PubMed Web of Science ®Google Scholar
• O’BrienSFurmanRRCoutreSEIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1B/2 trialLancet Oncol201415485824332241
   PubMed Web of Science ®Google Scholar
• ByrdJCBrownJRO’BrienSIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaN Engl J Med201437121322324881631
   PubMed Web of Science ®Google Scholar
• O’BrienSJonesJACoutreSEfficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE-17 trialBlood2014124327
   Web of Science ®Google Scholar
• JainPKeatingMWierdaWOutcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinibBlood20151252062206725573991
   PubMed Web of Science ®Google Scholar
• MaddocksKJRuppertASLozanskiGEtiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemiaJAMA Oncol20151808726182309
   PubMed Web of Science ®Google Scholar
• WoyachJAFurmanRRLiuTMResistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinibN Engl J Med20143702286229424869598
   PubMed Web of Science ®Google Scholar
• AlbitarAMaWDe DiosIHigh sensitivity testing shows multiclonal mutations in patients with CLL treated with BTK inhibitor and lack of mutations in ibrutinib-naive patientsBlood2015126716
   Google Scholar
• KamelSHortonLYsebaertLIbrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregationLeukemia20142978378725138588
   PubMedGoogle Scholar
• LevadeMDavidEGarciaCIbrutinib treatment affects collagen and von Willebrand factor-dependent platelet functionsBlood20141243991399525305202
   PubMed Web of Science ®Google Scholar
• ByrdJCHarringtonBO’BrienSAcalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemiaN Engl J Med201637432333226641137
   PubMed Web of Science ®Google Scholar
• BrownJRByrdJCCoutreSEIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemiaBlood20141233390339724615777
   PubMed Web of Science ®Google Scholar
• SharmanJPCoutreSEFurmanRRSecond interim analysis of a phase 3 study of idelalisib (ZYDELIG) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factorsBlood2014124330
   Web of Science ®Google Scholar
• JonesJAWachMRobakTResults of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL)J Clin Oncol201533Suppl7023
   Google Scholar
• JonesJAWachMRobakTUpdated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL)J Clin Oncol201634Suppl7515
   Google Scholar
• LampsonBLMatosTKimHTIdelalisib given front-line for the treatment of chronic lymphocytic leukemia results in frequent and severe immune-mediated toxicitiesBlood2015126497
   Web of Science ®Google Scholar
• PattonDTGardenOAPearceWPCutting edge: the phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cellsJ Immunol20061776598660217082571
   PubMed Web of Science ®Google Scholar
• CoutreSBarrientosJCBrownJRSafety of idelalisib in B-cell malignancies: integrated analysis of eight clinical trialsJ Clin Oncol201533Supple18030
   Google Scholar
• LampsonBLKasarSNMatosTRIdelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBlood201612819520327247136
   PubMed Web of Science ®Google Scholar
• BarrientosJCIdelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialOnco Targets Ther201692945295327274288
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyCHMP confirms recommendations for use of Zydelig2016 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Zydelig/human_referral_prac_000055.jsp&mid=WC0b01ac05805c516fAccessed November 17, 2016
   Google Scholar
• MarschitzIAnalysis of Bcl-2 protein expression in chronic lymphocytic leukemiaAm J Clin Pathol200011321922910664624
   PubMed Web of Science ®Google Scholar
• SamuelSTumilasciVFOliereSVSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemiaMol Ther20101820942103
   PubMed Web of Science ®Google Scholar
• CampàsCCosiallsAMBarragánMBcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cellsExp Hematol2006341663166917157163
   PubMed Web of Science ®Google Scholar
• TsujimotoYCossmanJJaffeECroceCMInvolvement of the bcl-2 gene in human follicular lymphomaScience1985228144014433874430
   PubMed Web of Science ®Google Scholar
• IqbalJNepalliVTWrightGBCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphomaJ Clin Oncol20062496196816418494
   PubMed Web of Science ®Google Scholar
• WilsonWHO’ConnorACzuczmanMSNavitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityLancet Oncol2010111149115921094089
   PubMed Web of Science ®Google Scholar
• RobertsAWSeymourJFBrownJRSubstantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory diseaseJ Clin Oncol20123048849622184378
   PubMed Web of Science ®Google Scholar
• SouersAJLeversonJDBoghaertERABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNat Med20131920220823291630
   PubMed Web of Science ®Google Scholar
• LeversonJDPhillipsDCMittenMJExploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapySci Transl Med20157279ra40
   PubMed Web of Science ®Google Scholar
• RobertsAWDavidsMSPagelJMTargeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemiaN Engl J Med201637431132226639348
   PubMed Web of Science ®Google Scholar
• RobakTDmoszynskaASolal-CélignyPRituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemiaJ Clin Oncol2010281756176520194844
   PubMed Web of Science ®Google Scholar
• WierdaWO’BrienSWenSChemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaJ Clin Oncol2005234070407815767647
   PubMed Web of Science ®Google Scholar
• WoyachJAJohnsonAJTargeted therapies in CLL: mechanisms of resistance and strategies for managementBlood201512647147726065659
   PubMed Web of Science ®Google Scholar
• StilgenbauerSEichhorstBScheteligJVenetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyLancet Oncol20161776877827178240
   PubMed Web of Science ®Google Scholar
• StratiPKeatingMJO’BrienSMEradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLLBlood20141233727373224705492
   PubMed Web of Science ®Google Scholar
• BöttcherSRitgenMFischerKMinimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trialJ Clin Oncol20123098098822331940
   PubMed Web of Science ®Google Scholar
• RobertsAWMaSBranderDMDetermination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)Blood2014124325
   Web of Science ®Google Scholar
• ChengSGuoALuPMaJColemanMWangYLFunctional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative k inase inhibitorsLeukemia20152989590025189416
   PubMed Web of Science ®Google Scholar
• ZhouQLeeGSBradyJA hypermorphic missense mutation in PLCγ2, encoding phospholipase Cy2, causes a dominantly inherited autoinflammatory disease with immunodeficiencyAm J Hum Genet20129171372023000145
   PubMed Web of Science ®Google Scholar
• WalliserCHermkesESchadeAThe phospholipase Cγ2 mutants R665W and L845F identified in ibrutinib-resistant chronic lymphocytic leukemia patients are hypersensitive to the Rho GTPase Rac2J Biol Chem2016291221362214827542411
   PubMed Web of Science ®Google Scholar
• YouleRJStrasserAThe BCL-2 protein family: opposing activities that mediate cell deathNat Rev Mol Cell Biol20089475918097445
   PubMed Web of Science ®Google Scholar
• VoglerMButterworthMMajidAConcurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemiaBlood20093011344034413
   Google Scholar
• ThijssenRGeestCRde RooijMFPossible mechanisms of resistance to the novel BH3-mimetic ABT-199 in in vitro lymph node models of CLL: the role of Abl and BtkBlood20131224188
   Google Scholar
• FresquetVRiegerMCarolisCGarcia-BarchinoMJMartinez-ClimentJAAcquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphomaBlood20141234111411924786774
   PubMed Web of Science ®Google Scholar
• ChoudharyGSAl-HarbiSMazumderSMCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignanciesCell Death Dis20156e159325590803
   PubMed Web of Science ®Google Scholar
• OppermannSYlankoJShiYHigh-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cellsBlood201612893494727297795
   PubMed Web of Science ®Google Scholar
• AcklerSMittenMJChenJNavitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin’s lymphoma tumours in vivoBr J Pharmacol201216788189122624727
   PubMed Web of Science ®Google Scholar
• MaSBranderDMSeymourJFDeep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a phase 1B studyBlood2015126830
   Web of Science ®Google Scholar
• FischerKFinkAMBishopHResults of the safety run-in phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and venetoclax (GDC0199/ABT199) with obinutuzumab and chlorambucil in patients with previously untreated CLL and coexisting medical conditionsBlood2015126496
   Web of Science ®Google Scholar
• Cervantes-GomezFLamotheBWoyachJPharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemiaClin Cancer Res2015213705371525829398
   PubMed Web of Science ®Google Scholar
• MD Anderson Cancer CenterVenetoclax and ibrutinib in patients with chronic lymphocytic leukemia (CLL) Available from: https://clinicaltrials.gov/ct2/show/NCT02756897NLM identifier: NCT02756897Accessed November 17, 2016
   Google Scholar
• TresckowJVCramerPBahloJCLL2-BIG: a novel treatment regime of bendamustine followed by GA101 maintenance in patients with chronic lymphocytic leukemia (CLL): interim results of a phase II trialBlood20151264151
   Google Scholar
• Ohio State University Comprehensive Cancer CenterBcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib in treating patients with relapsed, refractory, or previously untreated chronic lymphocytic leukemia Available from: https://clinicaltrials.gov/ct2/show/NCT02427451NLM identifier: NCT02427451Accessed November 17, 2016
   Google Scholar
• University of UlmTrial of ibrutinib plus venetoclax plus obinutuzumab in patients with CLL (CLL2-GiVe) Available from: https://clinicaltrials.gov/ct2/show/NCT02758665NLM identifier: NCT02758665Accessed November 17, 2016
   Google Scholar
• DeeksEDVenetoclax: first global approvalDrugs20167697998727260335
   PubMed Web of Science ®Google Scholar
• MerinoDLokSWVisvaderJETargeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancerOncogene2016351877188726257067
   PubMed Web of Science ®Google Scholar
• CramerPLangerbeinsPHallekMCombination of targeted drugs to control chronic lymphocytic leukemia: harnessing the power of new monoclonal antibodies in combination with ibrutinibCancer J201622626626841018
   PubMed Web of Science ®Google Scholar